Disclosed are methods of increasing survival of a subject having
cancer comprising applying an alternating
electric field to a
target site of the subject for a period of time, the alternating
electric field having a frequency and
field strength, wherein the
target site comprises one or more
cancer cells, and administering a therapeutically effective amount of a checkpoint inhibitor to the subject. Disclosed are methods of treating a subject having
cancer comprising applying an alternating
electric field to a
target site of the subject for a period of time, the alternating electric field having a frequency and
field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of a checkpoint inhibitor to the subject. In some aspects, the checkpoint inhibitor is Nivolumab, Pembrolizumab, or
Atezolizumab. Also disclosed are methods of increasing survival of a subject having non-
small cell lung cancer comprising: applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and
field strength, wherein the target site comprises one or more non-
small cell lung cancer cells, and administering a therapeutically effective amount of a checkpoint inhibitor to the subject. Disclosed are methods of treating a subject having non-
small cell lung cancer comprising: applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more non-small
cell lung cancer cells, and administering a therapeutically effective amount of a checkpoint inhibitor to the subject. In some aspects, the checkpoint inhibitor is ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (
trade name Libtayo), and dostarlimab (Jemperli),
atezolizumab (Tecentriq), durvalumab (Imfinzi), or avelumab (Bavencio).